Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day.

Eli Lilly's (LLY) stock surges 14% as its diabetes drug orforglipron meets Phase 3 goals, cutting weight by 8%. Read more ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

Lilly's once-daily diabetes pill showed strong A1C and weight-loss results, with approval filings expected in 2025--2026 ...

A STAT investigation last year revealed that UnitedHealth Group, which owns the country’s largest Medicare Advantage insurer, ...